Pulse Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. (PLSE) on August 6, 2020. The report discloses corporate governance changes, specifically the election of a new director and the appointment of committee members.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The Board of Directors increased its size by one member and elected Richard van den Broek to fill the vacancy, effective August 6, 2020. Mr. van den Broek was appointed to the Audit Committee (replacing Mitchell Levinson) and the Compensation Committee.
Compensation and Governance Details
- Annual Retainers: $40,000 for Board service, $10,000 for the Audit Committee, and $6,500 for the Compensation Committee.
- Initial Equity Grant: Stock option to purchase 32,500 shares, vesting over three years (one-third on the first anniversary, remainder monthly).
- Annual Equity Grant: Eligible for an annual option grant of 20,000 shares, vesting monthly over one year.
- Retainer Option Election: Mr. van den Broek may elect to convert cash retainers into stock options at a 3x multiplier of the cash value.
Risks and Contingencies
The filing states there are no family relationships between Mr. van den Broek and other directors or officers, and no reportable related party transactions exist. The press release accompanying this filing is furnished under Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the impact of the new director's biotechnology and pharmaceutical experience on the company's strategic direction.
- Review the total dilution impact of the initial 32,500 share option grant and potential future annual grants.
- Confirm the departure of Mitchell Levinson from the Audit Committee and the qualifications of the new committee composition.
- Check subsequent filings for the actual vesting schedule execution and any Retainer Option Elections made by the new director.